BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,130 filers reported holding BAXTER INTL INC in Q1 2022. The put-call ratio across all filers is 1.41 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $85,178,840 | +178.5% | 2,256,991 | +236.2% | 0.24% | +191.6% |
Q2 2023 | $30,582,195 | +320.8% | 671,251 | +274.6% | 0.08% | +260.9% |
Q1 2023 | $7,268,352 | +929.5% | 179,200 | +1893.8% | 0.02% | +1050.0% |
Q1 2022 | $706,000 | -9.8% | 8,988 | -1.4% | 0.00% | 0.0% |
Q4 2021 | $783,000 | -17.6% | 9,116 | -22.0% | 0.00% | 0.0% |
Q3 2021 | $950,000 | +50.6% | 11,684 | +49.2% | 0.00% | 0.0% |
Q2 2021 | $631,000 | -57.4% | 7,829 | -57.6% | 0.00% | 0.0% |
Q4 2020 | $1,482,000 | -94.5% | 18,475 | -94.5% | 0.00% | -96.6% |
Q3 2020 | $27,061,000 | +166.2% | 336,618 | +184.7% | 0.06% | +68.6% |
Q2 2020 | $10,167,000 | +78.7% | 118,226 | +73.7% | 0.04% | +66.7% |
Q4 2019 | $5,689,000 | -61.8% | 68,051 | -60.7% | 0.02% | -62.5% |
Q3 2019 | $14,911,000 | +864.5% | 173,317 | +812.2% | 0.06% | +1766.7% |
Q2 2019 | $1,546,000 | +99.2% | 19,000 | +100.0% | 0.00% | 0.0% |
Q1 2019 | $776,000 | -95.8% | 9,500 | -96.7% | 0.00% | -95.7% |
Q4 2018 | $18,646,000 | +8654.0% | 283,842 | +10270.6% | 0.07% | +6800.0% |
Q3 2018 | $213,000 | -66.9% | 2,737 | -68.6% | 0.00% | -50.0% |
Q2 2018 | $643,000 | -98.2% | 8,709 | -98.4% | 0.00% | -90.0% |
Q1 2018 | $35,116,000 | +1043.1% | 540,031 | +1036.9% | 0.02% | +300.0% |
Q4 2017 | $3,072,000 | +63.8% | 47,501 | +58.8% | 0.01% | +25.0% |
Q3 2017 | $1,876,000 | -61.7% | 29,912 | -64.1% | 0.00% | -66.7% |
Q2 2017 | $4,898,000 | +116.2% | 83,352 | +63.3% | 0.01% | +100.0% |
Q4 2016 | $2,265,000 | +33.5% | 51,036 | +35.0% | 0.01% | +20.0% |
Q2 2016 | $1,697,000 | -73.5% | 37,800 | -75.8% | 0.01% | -77.3% |
Q1 2016 | $6,400,000 | -91.3% | 156,166 | -91.9% | 0.02% | -89.3% |
Q4 2015 | $73,766,000 | +64.6% | 1,938,259 | +57.3% | 0.21% | +28.0% |
Q3 2015 | $44,813,000 | +941.2% | 1,232,521 | +1916.5% | 0.16% | +1241.7% |
Q2 2015 | $4,304,000 | +65.4% | 61,122 | +61.9% | 0.01% | +33.3% |
Q1 2015 | $2,602,000 | -69.6% | 37,749 | -67.6% | 0.01% | -60.9% |
Q4 2014 | $8,560,000 | +250.1% | 116,685 | +244.4% | 0.02% | +228.6% |
Q3 2014 | $2,445,000 | -14.1% | 33,876 | -13.7% | 0.01% | +600.0% |
Q2 2014 | $2,845,000 | -63.6% | 39,273 | -63.3% | 0.00% | -50.0% |
Q1 2014 | $7,825,000 | -31.3% | 107,018 | -34.7% | 0.00% | -96.2% |
Q4 2013 | $11,391,000 | -38.3% | 163,809 | -41.7% | 0.05% | -53.6% |
Q3 2013 | $18,475,000 | -37.6% | 281,191 | -34.1% | 0.11% | -53.5% |
Q2 2013 | $29,608,000 | +374.2% | 427,016 | +395.8% | 0.24% | +265.2% |
Q1 2013 | $6,244,000 | +209.1% | 86,120 | +183.8% | 0.07% | +200.0% |
Q4 2012 | $2,020,000 | – | 30,344 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |